Show simple item record

dc.contributor.authorSutherland, Sen
dc.contributor.authorAshley, Sen
dc.contributor.authorMiles, Den
dc.contributor.authorChan, Sen
dc.contributor.authorWardley, Andrew Men
dc.contributor.authorDavidson, Nen
dc.contributor.authorBhatti, Ren
dc.contributor.authorShehata, Men
dc.contributor.authorNouras, Hen
dc.contributor.authorCamburn, Ten
dc.contributor.authorJohnston, S R Den
dc.date.accessioned2010-08-04T10:39:45Z
dc.date.available2010-08-04T10:39:45Z
dc.date.issued2010-03-16
dc.identifier.citationTreatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience. 2010, 102 (6):995-1002 Br J Canceren
dc.identifier.issn1532-1827
dc.identifier.pmid20179708
dc.identifier.doi10.1038/sj.bjc.6605586
dc.identifier.urihttp://hdl.handle.net/10541/109035
dc.description.abstractBACKGROUND: The global lapatinib expanded access programme provided access to lapatinib combined with capecitabine for women with HER2-positive metastatic breast cancer (MBC) who previously received anthracycline, taxane and trastuzumab. METHODS: Progression-free survival (PFS) and safety data for 356 patients recruited from the United Kingdom are reported. Efficacy was assessed in 162 patients from the five lead centres, including objective tumour response rate (ORR), time to disease progression (TTP) and efficacy in those with central nervous system (CNS) metastases. Correlation of PFS and ORR with previous capecitabine treatment was also documented. RESULTS: Overall, PFS for the 356 UK patients was 21 weeks (95% CI: 17.6-24.7). In the 162 assessable patients, ORR was 21% (95% CI: 15-27%) and median TTP was 22 weeks (95% CI: 17-27). Efficacy was greater in capecitabine-naive patients (ORR 23 vs 16.3%, P=0.008). For 34 patients with CNS metastases, ORR was 21% (95% CI: 9-39%), with evidence of improvement in neurological symptoms, and median TTP was 22 weeks (95% CI: 15-28). CONCLUSIONS: Lapatinib combined with capecitabine is an active treatment option for women with refractory HER2-positive MBC, including those with progressive CNS disease.
dc.language.isoenen
dc.subjectBrain Canceren
dc.subjectBreast Canceren
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshBrain Neoplasms
dc.subject.meshBreast Neoplasms
dc.subject.meshCarcinoma
dc.subject.meshCohort Studies
dc.subject.meshDeoxycytidine
dc.subject.meshFemale
dc.subject.meshFluorouracil
dc.subject.meshGenes, erbB-2
dc.subject.meshGreat Britain
dc.subject.meshHealth Services Accessibility
dc.subject.meshHumans
dc.subject.meshMiddle Aged
dc.subject.meshQuinazolines
dc.subject.meshRetrospective Studies
dc.subject.meshSurvival Analysis
dc.subject.meshTreatment Outcome
dc.titleTreatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medicine, The Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, Fulham Road, Chelsea and Sutton, London, UK.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractBACKGROUND: The global lapatinib expanded access programme provided access to lapatinib combined with capecitabine for women with HER2-positive metastatic breast cancer (MBC) who previously received anthracycline, taxane and trastuzumab. METHODS: Progression-free survival (PFS) and safety data for 356 patients recruited from the United Kingdom are reported. Efficacy was assessed in 162 patients from the five lead centres, including objective tumour response rate (ORR), time to disease progression (TTP) and efficacy in those with central nervous system (CNS) metastases. Correlation of PFS and ORR with previous capecitabine treatment was also documented. RESULTS: Overall, PFS for the 356 UK patients was 21 weeks (95% CI: 17.6-24.7). In the 162 assessable patients, ORR was 21% (95% CI: 15-27%) and median TTP was 22 weeks (95% CI: 17-27). Efficacy was greater in capecitabine-naive patients (ORR 23 vs 16.3%, P=0.008). For 34 patients with CNS metastases, ORR was 21% (95% CI: 9-39%), with evidence of improvement in neurological symptoms, and median TTP was 22 weeks (95% CI: 15-28). CONCLUSIONS: Lapatinib combined with capecitabine is an active treatment option for women with refractory HER2-positive MBC, including those with progressive CNS disease.


This item appears in the following Collection(s)

Show simple item record